To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Dan Wetherill
Advertisement
Dan Wetherill is a partner at Beghou Consulting.
Articles by Dan Wetherill
Dan Wetherill offers three priorities for how pharma companies can better use data analytics to engage customers.
Advertisement
Latest Updated Articles
Data Analytics: Strength — and Solutions — in NumbersPublished: November 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
Could DTC Programs Help Simplify the Drug-Pricing System?
5
